Researchers want to understand how well an investigational medication, given along with current asthma treatment, may help to reduce asthma symptoms. Respond today to learn more.

Facts to know about asthma:

• Nearly 28 million people in the U.S. have asthma — about 1 in 12 people.
• Symptoms include shortness of breath, wheezing, coughing and tightness or pain in the chest.
• Asthma can be triggered by different things for different people — common allergens include seasonal pollen, mold spores, dust or pet dander.

Are you or someone you know frustrated with asthma that’s not in control?
Meet with an asthma research doctor!

Exclusive Opportunity: Limited Spots Available for a New Asthma Study!

Key Qualifications
• 18 and 75 years old
• Diagnosed with asthma
• Use regular daily inhaler to manage asthma symptoms

What to Expect if You Qualify
• Meet with a study doctor and complete health-related assessments
• Participate in 12 in-person visits over 15 months
• Access to study medication at no cost
• Reimbursement may be available for your time and effort

See if you qualify!

Call us: 786-772-0510

The GN02 study is a new clinical research study from Eli Lilly and Company. GN02 is a weight management study. It will test if an investigational medicine can safely reduce body weight in people with type 2 diabetes and obesity or overweight when compared to placebo.

Investigational medicine means it is still being tested in clinical research studies. A placebo looks the same as an investigational medicine but does not have any real medicine in it.

Can I join this study?

Yes, you may be able to join the study if you:

  • are aged 18 to 75 years
  • cannot become pregnant
  • have type 2 diabetes that you treated with diet and exercise alone or with a stable dose of metformin.
  • have not taken insulin in the past year, and
  • have a BMI of 27kg/m 2 or more

BMI stands for body mass index. It is a number that compares a person’s weight to their height. It can be used to tell if a person may be at risk of some health conditions.

For more information: 786-772-0510

This clinical trial’s purpose is to test a new study drug, called AZD0780. The study drug is a small molecule PCSK9 inhibitor that aims to lower the levels of “bad cholesterol” in the blood.

Volunteers who join the trial will take AZD0780(study drug) orally, every day for 12 weeks, which is about three months. Your participation in the study will help to determine the
effectiveness, safety, and tolerability of AZD0780(study drug) and how it affects LDL-C (bad cholesterol) levels and levels of other types of fat in your blood.

You may qualify if you:

  • Are male or female of non-childbearing potential within an age range from 18 to 75 years.
  • Fasting LDL-C levels (bad cholesterol): Between 70mg/dL (1.8 mmol/L) and < 190 mg/dL (4.9 mmol/L).
  • Fasting triglycerides: < 400 mg/dL (< 4.52 mmol/L).
  • Are receiving moderate or high-intensity statin therapy as per ACC/AHA (at least 2 months prior to screening).
  • Body mass index (BMI): ≥ 19.0 kg/m2.
  • Are capable of providing signed informed consent and comply with study requirements.

Contact us for more information: 786-772-0510

Skip to content
Enable Notifications OK No thanks
NULL